Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes
University of Alabama at Birmingham
70 participants
May 1, 2026
INTERVENTIONAL
Conditions
Summary
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
Eligibility
Inclusion Criteria1
- Healthy adult
Exclusion Criteria2
- No prior history of pneumococcal vaccination
- No immunosuppressing medications or chronic diseases that affect immune function
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PCV
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07135453